WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 555755
CAS#: 374703-78-3
Description: PKG drug G1 is an activator of protein kinase GIα (PKGIα).
MedKoo Cat#: 555755
Name: PKG Drug G1
CAS#: 374703-78-3
Chemical Formula: C13H11N3OS
Exact Mass: 257.0623
Molecular Weight: 257.311
Elemental Analysis: C, 60.68; H, 4.31; N, 16.33; O, 6.22; S, 12.46
Synonym: PKG Drug G1
IUPAC/Chemical Name: 5-[(2-methyl-1H-indol-3-yl)methylene]-2-thioxo-4-imidazolidinone
InChi Key: SNLLEQAPNVMOOT-WDZFZDKYSA-N
InChi Code: InChI=1S/C13H11N3OS/c1-7-9(6-11-12(17)16-13(18)15-11)8-4-2-3-5-10(8)14-7/h2-6,14H,1H3,(H2,15,16,17,18)/b11-6-
SMILES Code: O=C(/C(N1)=C/C2=C(C)NC3=C2C=CC=C3)NC1=S
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
| Biological target: | PKG agent G1 targets C42 of PKG Iα. |
| In vitro activity: | TBD |
| In vivo activity: | TBD |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMF | 25.0 | 97.16 | |
| DMSO | 48.67 | 189.14 | |
| Ethanol | 3.0 | 11.66 |
The following data is based on the product molecular weight 257.311 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | TBD |
| In vitro protocol: | TBD |
| In vivo protocol: | TBD |
1. Burgoyne, J.R., Prysyazhna, O., Richards, D.A., et al. Proof of principle for a novel class of antihypertensives that target the oxidative activation of PKG Iα (protein kinase G Iα). Hypertension 70(3), 577-586 (2017).
